Crescent Biopharma, Inc. (CBIO)

14.15 USD-1.53%close 2026-11-13Healthcare
Gurus hold1popularity #1909 of 1982
Net buying (quarter)+$291.8K1 buying · 0 selling
Market Cap$550.4M52 Week Range: 8.94 – 26.98
P/E (TTM)Price/Earnings: share price over annual profit — what you pay per $1 of earnings. Compare within the sector.LossEPS -2.81
The live quote provider is unreachable; the last known close is shown.

Crescent Biopharma, Inc. (CBIO) is not among the 30 most-held stocks of the tracked superinvestor set. Price 14.15 USD; market cap $550.4M.

Guru Ownership

Popularity rank#1,909 of 1,982 securities
gurus hold it1
Net activity this quarter+$291.8K

Guru count: the consensus-panel funds (wide books such as Citadel or Renaissance excluded) holding the stock at quarter end; the header and the history table use the same definition.

What changed this quarter
$291.8K · 1 new buys · 0 added $0.00 · 0 reduced · 0 sold out1 net buyers · 0 net sellers
Top 5 by conviction
Top 5 by value

Price & valuation

Prev Close14.37
Open—
Day Range—
52 Week Range8.94 – 26.98
Volume—
Avg Volume (3M)—
Market Cap$550.4MSEC 10-Q, 11/11/2026
BetaVolatility vs the market. Above 1: swings harder than the index.1.572 years, weekly, vs SPY
P/E (TTM)Price/Earnings: share price over annual profit — what you pay per $1 of earnings. Compare within the sector.LossSEC 10-Q, 09/30/2026
EPS (TTM)Annual net profit per share.-2.81SEC 10-Q, 09/30/2026
Dividend YieldAnnual dividend over share price.—

Pro Feature

This section is exclusive to Fundocap Pro. Full holdings tables, consensus trades, ownership analysis, backtests and exports unlock with Pro.

Upgrade to Pro

About

SectorHealthcare
Industry—
Employees—
Website—

Frequently Asked Questions

Which superinvestors own CBIO?

Crescent Biopharma, Inc. (CBIO) is not among the 30 most-held stocks of the tracked superinvestor set.

Is institutional sentiment on CBIO bullish or bearish?

CBIO is not among the 30 most-held stocks of the superinvestor set, so net buyer/seller counts are not computed for it.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.